Timothy P.  Kelly net worth and biography

Timothy Kelly Biography and Net Worth

Insider of Homology Medicines
Tim Kelly brings more than 20 years of global product development and manufacturing experience to Homology encompassing preclinical to commercialization with a focus on rare disease therapies and biologics. He joined Homology from Sarepta Therapeutics, where he served as Head of Technical Operations and was responsible for the process development and manufacturing strategy for Sarepta’s gene therapy programs, and the development, commercialization and scale-up of novel RNA-based chemical therapies. Prior, Mr. Kelly spent eight years at Shire, most recently as Senior Vice President and Head of Biologics Operating Unit, where he was responsible for technical operations for all clinical and commercial biologics and gene therapy products, including internal and external manufacturing. At Shire, Mr. Kelly also served as Interim Head of Technical Operations, Head of Product Strategy & Planning, Head of Global External Operations and Head of Global Supply Chain. He was previously the Head of Technical Operations at UCB in Belgium, with direct management of operations in Belgium, Switzerland, the United Kingdom, Germany, Ireland, Japan and India. Mr. Kelly also held roles of increasing responsibility at Biogen Idec, including Senior Director of International Operations. Mr. Kelly holds a B.S. with emphasis in Engineering Mechanics from the United States Air Force Academy and an M.B.A. from Troy University.

What is Timothy P. Kelly's net worth?

The estimated net worth of Timothy P. Kelly is at least $0.00 as of February 2nd, 2021. Mr. Kelly owns 1,000 shares of Homology Medicines stock worth more than $0 as of March 28th. This net worth approximation does not reflect any other assets that Mr. Kelly may own. Learn More about Timothy P. Kelly's net worth.

How do I contact Timothy P. Kelly?

The corporate mailing address for Mr. Kelly and other Homology Medicines executives is ONE PATRIOTS PARK, BEDFORD MA, 01730. Homology Medicines can also be reached via phone at (781) 301-7277 and via email at [email protected]. Learn More on Timothy P. Kelly's contact information.

Has Timothy P. Kelly been buying or selling shares of Homology Medicines?

Timothy P. Kelly has not been actively trading shares of Homology Medicines during the last quarter. Most recently, Timothy P. Kelly sold 2,812 shares of the business's stock in a transaction on Wednesday, January 5th. The shares were sold at an average price of $1.89, for a transaction totalling $5,314.68. Learn More on Timothy P. Kelly's trading history.

Who are Homology Medicines' active insiders?

Homology Medicines' insider roster includes Timothy Kelly (Insider), Albert Seymour (Insider), W. Smith (CFO), and Arthur Tzianabos (CEO). Learn More on Homology Medicines' active insiders.

Are insiders buying or selling shares of Homology Medicines?

During the last twelve months, insiders at the sold shares 4 times. They sold a total of 43,728 shares worth more than $13,375.58. The most recent insider tranaction occured on January, 9th when Director Arthur Tzianabos sold 26,074 shares worth more than $7,431.09. Insiders at Homology Medicines own 16.1% of the company. Learn More about insider trades at Homology Medicines.

Information on this page was last updated on 1/9/2024.

Timothy P. Kelly Insider Trading History at Homology Medicines

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2022Sell2,812$1.89$5,314.68View SEC Filing Icon  
9/3/2021Sell108$3.85$415.80View SEC Filing Icon  
2/2/2021Sell1,000$6.50$6,500.001,000View SEC Filing Icon  
1/12/2021Sell1,000$6.50$6,500.001,000View SEC Filing Icon  
3/17/2020Sell2,630$6.51$17,108.15View SEC Filing Icon  
9/5/2019Sell2,332$9.97$23,250.04
See Full Table

Timothy P. Kelly Buying and Selling Activity at Homology Medicines

This chart shows Timothy P Kelly's buying and selling at Homology Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Homology Medicines Company Overview

Homology Medicines logo
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.44
Low: $0.29
High: $0.93

2 Week Range

Now: N/A

Volume

401,467 shs

Average Volume

249,289 shs

Market Capitalization

$54.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A